--- title: "Webinar: Advancing Antibody-Drug Conjugate Therapies: Key Preclinical and Regulatory Strategies for Clinical Success" description: "Webinar: Advancing Antibody-Drug Conjugate Therapies: Key Preclinical and Regulatory Strategies for Clinical Success" image: https://td2inc.com/hubfs/thumb-webinar-clinical-success.png --- ×   [![td2-logo](https://td2inc.com/hubfs/td2-logo.png "td2-logo")](https://td2inc.com/?hsLang=en) ![Search Site](https://td2inc.com/hubfs/Assets/Icon/search-icon-1.png) [![td2-logo](https://td2inc.com/hubfs/td2-logo.png "td2-logo")](https://td2inc.com/?hsLang=en) ![Search Site](https://td2inc.com/hubfs/Assets/Icon/search-icon-1.png) ![video](https://td2inc.com/hs-fs/hubfs/thumb-webinar-clinical-success.png?width=300&name=thumb-webinar-clinical-success.png) Antibody-drug conjugates represent a pivotal advancement in oncology, offering highly targeted cancer treatments that combine precision and potency. However, developing these therapies comes with significant challenges, from their intricate design to safety and resistance issues. This webinar will provide a comprehensive overview of these obstacles and deliver actionable insights into overcoming them. Attendees will gain a deep understanding of preclinical strategies that address [antibody-drug conjugate development](https://td2inc.com/lp-advancing-adc-therapeutics-in-oncology?hsLang=en) hurdles, including *in vitro* and *in vivo* evaluation methods essential for optimizing antibody-drug conjugate performance. Additionally, the session will cover the regulatory landscape, emphasizing the importance of early engagement with regulatory bodies and strategic planning to ensure smooth Investigational [New Drug (IND) submissions and regulatory approval](https://td2inc.com/regulatory-support?hsLang=en). The webinar also features case studies of successful antibody-drug conjugate therapies, highlighting the key factors that contributed to their approval and clinical success. These real-world examples will showcase innovative approaches that are shaping the future of antibody-drug conjugate development. The attendees will learn how to streamline the path from preclinical evaluation to clinical success, ensuring their antibody-drug conjugate therapies are positioned for success in a highly competitive market. ### Download this webinar to learn: - The complexities of antibody-drug conjugate design, safety concerns and mechanisms of resistance in oncology drug development - *In vitro* and *in vivo* models that optimize antibody-drug conjugate performance, including essential assays for antibody-drug conjugate efficacy and safety - How early engagement with regulatory agencies and strategic study design can streamline the IND submission process - Real-world case studies of successful antibody-drug conjugate therapies and emerging trends that are shaping the future of antibody-drug conjugate development ### Watch Now ## CONTACT US ## Get Started. Have questions about how TD2 can assist with your regulatory needs? Reach out to our expert staff today to get started. [Get Started Now](https://td2inc.com/contact-us/?hsLang=en) × [![td2-logo-footer](https://td2inc.com/hs-fs/hubfs/td2-logo.png?width=160&name=td2-logo.png)](https://td2inc.com/?hsLang=en) Office 13208 E. Shea Blvd, Suite 100 Scottsdale, AZ 85259 Phone (602) 358-8300 Connect with us - - ![td2-logo-footer](https://td2inc.com/hs-fs/hubfs/Assets/Logo/acclac-logo.png?width=139&name=acclac-logo.png) © 2026 Translational Drug Development. All Rights Reserved. [Terms and Conditions](https://td2inc.com/terms-and-conditions?hsLang=en) | [Privacy Policy](https://td2inc.com/privacy-policy?hsLang=en)